ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Interactive Brokers

Interactive Brokers
Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
Sign In Premium IconPremium Help Menu
S&P 500
5,055.72
-0.12%
US Tech 100
17,265.60
0.13%
Dow Jones
37,862.68
0.34%
Brent Oil
89.625
-0.28%
Bitcoin
61,748.72
-2.64%
Registration Strip Icon for discussion Register to chat with like-minded investors on our interactive forums.
Get Started
Symbol: 
Date:
Sort by:
DateTimeSourceHeadlineSymbolCompany
04/16/202412:00PMBusiness WirePowerSchool to Announce First Quarter 2024 Financial Results on May 7, 2024NYSE:PWSCPowerSchool Holdings Inc
04/16/202412:00PMGlobeNewswire Inc.ORAPI : CHIFFRE D’AFFAIRES T1 2024 - Recul des ventes de 2,1% à périmètre comparableEU:ORAPOrapi
04/16/202412:00PMBusiness WireAmagi Integrates Intertrust ExpressPlay DRM for Delivering Premium Content to FAST Service Platforms
04/16/202412:00PMGlobeNewswire Inc.OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes EffectiveTG:6OPOSE Immunotherapeutics
04/16/202412:00PMBusiness WireMusiCares® to Hold The Day That Music Cares on April 26
04/16/202412:00PMGlobeNewswire Inc.ORAPI : CHIFFRE D’AFFAIRES T1 2024 - Recul des ventes de 2,1% à périmètre comparableLSE:0ICIOrapi Sa
04/16/202412:00PMGlobeNewswire Inc.OSE Immunotherapeutics annonce l’entrée en vigueur de la licence mondiale pour développer un anticorps monoclonal innovant dans le traitement de l’inflammation chroniqueTG:6OPOSE Immunotherapeutics
04/16/202412:00PMBusiness WireGiada De Laurentiis Announces New Giadzy Membership Community
04/16/202412:00PMBusiness WireBona Releases 2023 Sustainability Report
04/16/202412:00PMGlobeNewswire Inc.Tonner Drones annonce son repositionnement stratégique
04/16/202412:00PMBusiness WireSMAIO publie ses résultats annuels 2023EU:ALSMASMAIO SA
04/16/202412:00PMGlobeNewswire Inc.Tonner Drones Announces Strategic Repositioning
04/16/202412:00PMGlobeNewswire Inc.OSE Immunotherapeutics annonce l’entrée en vigueur de la licence mondiale pour développer un anticorps monoclonal innovant dans le traitement de l’inflammation chroniqueLSE:0RADOse Immunotherapeutics Sa
04/16/202412:00PMGlobeNewswire Inc.Genk Green Logistics enters into an agreement with Neovia Logistics Services for the expansion of their existing warehouse by +/- 10,000 m²
04/16/202412:00PMBusiness WireMirantis Investor and Former VMware Executive Joins Board of Directors
04/16/202412:00PMBusiness WireSMAIO Publishes its 2023 Annual ResultsEU:ALSMASMAIO SA
04/16/202412:00PMGlobeNewswire Inc.Foncière 7 Investissement : Communiqué de mise à disposition du rapport financier annuel au 31 décembre 2023EU:LEBLLcx Leblanc Chr
04/16/202412:00PMBusiness Wirelululemon Unveils Team Canada Summer Athlete Kit for Paris 2024 Olympic and Paralympic Games in Partnership with the Canadian Olympic Committee and Canadian Paralympic CommitteeNASDAQ:LULULululemon Athletica Inc
04/16/202412:00PMGlobeNewswire Inc.OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes EffectiveEU:OSEOSE Immunotherapeutics
04/16/202412:00PMBusiness WireLyra Health Convenes Global Human Resources Leaders to Promote Workforce Mental Health at Breakthrough 2024
04/16/202412:00PMGlobeNewswire Inc.GROUPE PARTOUCHE : Calendrier de distribution du dividendeEU:PARPGroupe Partouche
04/16/202412:00PMGlobeNewswire Inc.Leading the Industry in Sides, eXp Realty Celebrates Its Agents' Remarkable Achievements With the Top Producers Lists for 2023NASDAQ:EXPIeXp World Holdings Inc
04/16/202412:00PMGlobeNewswire Inc.OSE Immunotherapeutics’ Global License to Develop a Novel Monoclonal Antibody for the Treatment of Chronic Inflammation Becomes EffectiveLSE:0RADOse Immunotherapeutics Sa
04/16/202412:00PMGlobeNewswire Inc.CISA, DHS S&T and OpenSSF Announce Global Launch of Software Supply Chain Open Source Project
04/16/202412:00PMGlobeNewswire Inc.Genk Green Logistics enters into an agreement with Neovia Logistics Services for the expansion of their existing warehouse by +/- 10,000 m²
04/16/202412:00PMGlobeNewswire Inc.GROUPE PARTOUCHE : Calendrier de distribution du dividendeLSE:0R62Groupe Partouche Sa
04/16/202412:00PMGlobeNewswire Inc.OSE Immunotherapeutics annonce l’entrée en vigueur de la licence mondiale pour développer un anticorps monoclonal innovant dans le traitement de l’inflammation chroniqueEU:OSEOSE Immunotherapeutics
04/16/202412:00PMGlobeNewswire Inc.Haffner Energy: a broader positioning and a new website to better serve our addressable market in Europe and the rest of the worldEU:ALHAFHaffner Energy SA
04/16/202412:00PMGlobeNewswire Inc.Foncière 7 Investissement : Communiqué de mise à disposition du rapport financier annuel au 31 décembre 2023LSE:0JJWFonciere 7 Investissement Sa
04/16/202412:00PMBusiness WireEsker Q1 2024 Sales Activity

Your Recent History

USOTC
ABQQ
AB (PK)
USOTC
FSRN
Fisker (PK)
USOTC
ILST
International Star (PK)
USOTC
APRU
Apple Rush (PK)
NASDAQ
SEV
Sono Group NV
USOTC
XERI
Xeriant (QB)
USOTC
NSAV
Net Savings Link (PK)
USOTC
GDVM
Global Developments (PK)
NASDAQ
TSLA
Tesla
NASDAQ
JAGX
Jaguar Health
USOTC
RNVA
Rennova Health (PK)
USOTC
IQST
iQSTEL (QX)
USOTC
FORW
Forwardly (PK)
USOTC
MVNT
Movement Industries (PK)
USOTC
ENZC
Enzolytics (PK)
USOTC
MIKP
Mike The Pike Productions (PK)
Delayed Upgrade Clock
ADVFN Logo

United States
Company
Business
Popular
Get The App

Support: 1-888-992-3836 | support@advfn.com

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

© 2024 ADVFN PLC - All Rights Reserved